Skip to main content
Fig. 17 (abstract P217). | Journal for ImmunoTherapy of Cancer

Fig. 17 (abstract P217).

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Fig. 17 (abstract P217).

Survival curve of DC-based combination therapy in RCC mouse model. DC monotherapy showed a 50% increase in median OS compared to the PBS group (42 vs 28 days). DC + Sutent combination therapy did not show increased OS compared to monotherapy with DCs or Sutent (40 vs 42 or 43 days). DC + aPD-1 combination therapy showed significantly increased median OS compared to monotherapy with DCs or aPD-1 (67 vs 42 or 34.5 days). DC + Sutent + aPD-1 combination therapy showed significantly increased media OS (>104 days) compared to all other groups tested

Back to article page